Omeros (OMER) Q3 2026 earnings review
Omeros transplant drug generates real cash, but Europe rejects it
Omeros, a Seattle biotechnology company, proved its transplant drug can generate cash on its own while losing its bid for European approval. Third-quarter net sales of Yartemlea rose 26% from the prior quarter to $36 million, lifting operating cash flow to $13 million without the one-time partner payment that propped up the second quarter. Chief executive Gregory Demopulos said sales growth continued into the fourth quarter as extra Medicare hospital payments took effect on October 1.
| Yartemlea net sales | $35.9M +26% from last quarter |
|---|---|
| Profit per share, excluding one-offs | $0.06 $0.02 last quarter |
| Operating cash flow | $13.3M $4.1M last quarter |
| European drug application | Rejected negative opinion kept on appeal in October |
โ๏ธ Verdict: ๐ข Bullish
The story got better because the United States launch is now self-funding the business through genuine operating leverage, pushing profit excluding one-offs to $5 million. The bad news: European regulators rejected the drug again on appeal in October, and hospital discounts under the federal 340B programme widened from 11.5% to 14% of gross sales.
The question now is whether United States sales can keep climbing fast enough to fund five clinical programmes without a European market. Either new Medicare inpatient payments unlock the remaining transplant centres, or wider outpatient discounts and fewer vials per patient slow revenue per hospital. Fourth-quarter sales and the hospital count in the quarterly filing will tell.
๐ Bull Case
Yartemlea Launch Drives Real Cash Generation
"YARTEMLEA sales continued to grow during the third quarter, delivering consecutive quarters of positive operating cash flow," chief executive Gregory Demopulos said. Yartemlea is the Seattle biotech group's only approved drug, used to treat TA-TMA, a deadly blood-vessel complication after stem cell transplants. Last quarter's $4.1 million of operating cash flow leaned on a one-time $3.3 million inventory payment from partner Novo Nordisk, so underlying cash generation was barely breakeven.
This quarter proved the drug can fund the business on its own. Net sales rose 26% from last quarter to $35.9 million, and operating cash flow jumped to $13.3 million without that one-off reimbursement. On October 1, Medicare started paying hospitals up to $287,079 in extra inpatient reimbursement per case under a new technology add-on programme (NTAP), and Omeros hired 16 field and nurse educators to train transplant staff.
What to watch: fourth-quarter net sales, which will be the first to include the extra Medicare inpatient payments. Another quarter of double-digit sequential growth would show the new hospital payments are bringing in inpatient orders.
Sales Leverage Pushes Operating Margin to 12.5%
A single-drug launch only works financially if revenue grows faster than the cost of the sales force and clinical trials. In the second quarter, Omeros barely broke even on operations, earning $74,000 on $28.5 million of net sales. In the third quarter, operating income reached $4.5 million, lifting the operating margin by 12.3 percentage points from last quarter to 12.5%, by our math.
- Selling and overhead costs: 40.5% of net sales, down 8.1 percentage points from last quarter by our math
- Research and development costs: 44.7% of net sales, down 3.7 percentage points from last quarter by our math
- Cost of making the product: 2.3% of net sales, leaving a 97.7% gross margin
- Profit excluding one-offs: $4.7 million, up from $1.8 million last quarter
What to watch: cost of product sales as a share of revenue over the next two quarters. The drug maker pays almost nothing to make each vial today because it wrote off the inventory before approval, so margins will face a real test once that early supply runs out.
๐ป Bear Case
European Regulators Rejected Yartemlea on Appeal
Omeros wanted to sell Yartemlea across Europe using the same clinical trial data that won approval in the United States. In June 2026, the European Medicines Agency's scientific committee (CHMP) turned down the application, and Demopulos asked for a formal re-examination with outside transplant specialists.
In October, the European committee "issued a negative opinion on our marketing authorization application (MAA) for narsoplimab in TA-TMA following re-examination of its original negative opinion". A failed appeal closes the standard regulatory path to the European market. Because Omeros has no other approved medicine, losing Europe leaves the commercial business entirely dependent on United States transplant centres and smaller international named-patient programmes.
What to watch: any management update on whether a European partner is still possible or if a new clinical trial is required. Without Europe, United States hospital adoption must carry the entire pipeline budget.
Hospital Discounts Rise as Sales Growth Slows
Demopulos wants "earlier recognition of TA-TMA and timely treatment with YARTEMLEA" to become standard transplant care, calling the drug "an endothelial injury drug with broad therapeutic potential". Yet the third-quarter numbers show sequential net revenue growth slowing from 188% in the second quarter to 26%, while pricing discounts took a bigger bite out of gross sales.
The gap between gross billings and net revenue widened by 2.5 percentage points to 14.0%. The biotech group said the jump came from higher outpatient buying under the federal 340B programme, which requires drug makers to give steep discounts to qualifying hospitals. At the same time, the press release gave no update on how many of the 175 US transplant centres have ordered the drug, a figure that stood at 73 in June.
What to watch: the gross-to-net discount rate in the first quarter of 2027, when new Medicare rules for 340B outpatient reimbursement begin. If the discount climbs past 15% while sequential growth slows again, outpatient discounts are eroding the revenue gained from new hospitals.
Risks this quarter didn't answer
Several standing risks from the launch, the balance sheet and the clinical pipeline either worsened slightly or received no updated numbers in the press release.
- Transplant centre adoption: ordering accounts (73 in Q2) and hospital formulary approval rates (55โ60% in Q2) were not in the release; the quarterly filing or call must supply them.
- Cash versus debt buybacks: paying $60.2 million in July to retire $30.5 million of 2029 convertible notes cut potential dilution by 4.9 million shares, yet it also helped drop cash and short-term investments by 28% from June to $95.3 million.
- Addiction trial delay: enrollment for the OMS527 cocaine use disorder trial slipped from year-end 2026 to the first quarter of 2027 "to address FDAโs request for additional nonclinical information before initiating the inpatient clinical trial".
- Accounting swings: a $62.0 million non-cash loss on the 2029 note derivative pushed GAAP net loss to $57.4 million, and 6.5 million convertible note shares still sit in the background.
What to watch: the quarterly Form 10-Q filing for the updated count of ordering transplant centres and the exact cash flow statement.
๐ฒ Other KPIs
Receivables โ money owed by drug wholesalers and hospitals for delivered vials โ more than doubled from $10.9 million at the end of 2025 and $12.0 million in March. The build tracks the first three quarters of Yartemlea commercial billings as hospitals take normal payment terms.
Basic weighted-average shares rose 10.1% from 66.3 million a year ago because of stock sales completed in late 2025 before the drug launch. From the second quarter, the count edged up 1.2% despite the company buying back 843,000 shares in the first half of 2026.
๐ฎ Guidance
Cut. The biotech group pushed the start of patient enrollment from the end of 2026 into the first quarter of 2027. It is running an extra laboratory study to answer a safety question from the Food and Drug Administration, marking the fifth time the start date has moved out since 2024.
Cut. Management softened the start target for its two 50-to-60-patient studies in acute respiratory distress syndrome (ARDS) and pediatric TA-TMA prevention from year-end 2026 to late 2026 or early 2027, waiting on ethics board sign-offs.
Unchanged. The company kept its late-2027 target to begin human testing of OMS805, its experimental treatment for acute myeloid leukemia, a blood and bone marrow cancer. Laboratory safety work and manufacturing for the first clinical batches are underway.
โ Key Questions
How many transplant centres have ordered Yartemlea so far?
At the end of June, 73 of the 175 US transplant centres had ordered the drug, and 55% to 60% of top centres had approved it on their formularies. Leaving both figures out of the third-quarter release hides whether growth came from new hospitals or repeat orders.
Why did management stop planning to share patient counts?
On the fourth-quarter 2025 call, the chief executive promised patient numbers in the first quarter, then in the second quarter said the company only sees vial shipments. Without vials per patient or treatment length, investors cannot tell if early demand is a one-time wave.
What is the European plan after the failed appeal?
The European regulator confirmed its rejection of Yartemlea in October. Management mentioned international regulatory approvals and named-patient programmes, yet has not said whether full European approval would require a new clinical trial.
When will Novo Nordisk pay the near-term milestones?
Omeros is eligible for up to $100 million in near-term milestone payments as Novo Nordisk moves zaltenibart into a Phase 3 trial. With cash down to $95.3 million after the July debt buyback, the timing of that cash matters for funding the pipeline.
